Stifel analyst David Grossman raised the firm’s price target on OptimizeRx (OPRX) to $21 from $18 and keeps a Buy rating on the shares. Revenue for the quarter materially outperformed, which drove significant EPS outperformance, the analyst tells investors in a research note. The firm added that it believes there’s a foundation for ongoing double-digit growth and expanding margins.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $32 from $27 at Roth Capital
- OptimizeRx price target raised to $24 from $20 at Lake Street
- OptimizeRx price target raised to $28 from $18 at B. Riley
- OptimizeRx price target raised to $24 from $23 at Citizens JMP
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance